Tag Archives: TB

Outlook “Gloomy” for TB Investment

The approval last year of Johnson & Johnson’s (J&J) treatment for tuberculosis (bedaquiline) — at the time the first TB drug approval in 40 years — “remains an exception to the generally gloomy outlook” for investment in TB R&D, writes Andrew Ward in this week’s Financial Times.
Posted in Emerging Markets, Global, Strategy | Also tagged , , , , | Leave a comment

TB: A Faster Pace in Progress Against the Wasting Disease

Multidrug resistant [MDR] TB is the front line in the global battle against infectious disease. It accounts for more than 5 per cent of new cases of TB, which itself takes more than 2 million lives per year – a death toll second only to HIV.  More important, multidrug resistant TB is now found in […]
Posted in Global | Also tagged , | 1 Comment

Industry Optimism for Advancing TB Research

Scientists optimistic new combination regimens will improve TB treatment and reduce drug resistance, writes Jill Wechsler, Pharm Exec‘s Washington Editor. In honor of World TB Day March 24, research organizations and international health agencies announced important advances in the development of new therapies for stemming the spread of increasingly lethal tuberculosis strains. Each year, nearly […]
Posted in FDA, Global, healthcare, Op-Ed | Also tagged , , | Leave a comment

TB Alliance Trumpets New, Improved Drugs at World Health Assembly

Like polio and leprosy, developed countries have long since tamed tuberculosis. But even now, other parts of the world continue to struggle against the disease, with nearly all (98 percent) of TB’s 1.7 million worldwide deaths occurring in developing countries. TB’s high comorbidity with HIV infections has recently added another level of urgency to efforts […]
Posted in Corporate Responsibility, Emerging Markets, Global, R&D | Also tagged , , , , , , , , , | Leave a comment
  • Categories

  • Meta